cCAM Biotherapeutics Ltd.
http://ccam-bio.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From cCAM Biotherapeutics Ltd.
Will AI Expertise Push Canada Forward As A Biopharma Hub?
In Canada, an impressive roster of machine learning companies and institutions highlights the research being conducted there. However, a paucity of VC funding and few experienced C-suite leaders has stunted the commercialization of great ideas.
Asia Deal Watch: Kelun Partners With Merck A Third Time, Optioning Rights To Seven ADCs
Already partnered on antibody-drug conjugates and a Phase III breast cancer candidate, Merck could pay up to $9.3bn under its third pact in 2022 with Kelun. Eisai divests Fycompa to Catalyst.
The Future Is Non-Hormonal: Contraceptive Market Crawls Into The 21st Century
Despite patient dissatisfaction, contraceptive options have made little advancement since the turn of the century – but a cohort of novel, non-hormonal products could see this all change.
Deal Watch: Lilly, Innovent Build On Long Alliance To Partner On Three Cancer Drugs
Under deal amendment, Innovent gets Asia rights to Cyramza, Retevmo and pirtobrutinib.
Company Information
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice